Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 63% · fresh
- Computed at
- 2026-09-22T00:11:53.882018+00:00
- Claimed
- 90
- Reported
- 80
- Verified
- 70
- Gap
- +20
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-09-22
Track; not yet
- Why
- Genuine, FDA-confirmed first-in-class approval (myostatin inhibition added on top of SMN2-directed SMA therapy) with a statistically significant but modest efficacy signal (2.2-point HFMSE benefit, p=0.0121) and a real, labeled fracture-risk trade-off — notable enough to register, not yet mature enough (no real-world outcomes data, launched days ago) to call adopted standard of care.
- Next
- Monitor post-marketing fracture surveillance, payer/reimbursement decisions, and Scholar Rock's first commercial-quarter ISEMBYLD revenue disclosure; revisit if the EMBRAZE (tirzepatide combination) Phase 2 program reads out further or the FSHD Fast Track / Phase 2 FORGE program advances.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 1
- Tier 2
- 1
- Tier 3
- 4
- Supports
- 3
- Contradicts
- 2
- Context
- 1
- Latest observed
- 2026-09-11
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-09-21 Reading moved from ready to ready.